Beamr video compression achieves up to 50% improvement for AVs
SEATTLE—Achieve Life Sciences, Inc. (NASDAQ:ACHV), a small-cap biotech company with a market capitalization of $93 million, recently reported that its Chief Financial Officer, Mark Oki, purchased 10,000 shares of the company’s common stock. The transaction took place on March 17, 2025, at a weighted average price of $2.8887 per share, amounting to a total investment of $28,887. According to InvestingPro data, this purchase comes as the stock trades near its 52-week low of $2.51.
The acquisition was disclosed in a Form 4 filing with the Securities and Exchange Commission. Following this purchase, Oki now holds 10,000 shares of Achieve Life Sciences directly. The stock has shown significant volatility, with analyst price targets ranging from $10 to $30, according to InvestingPro data.
The transaction reflects Oki’s direct ownership in the company, which specializes in in vitro and in vivo diagnostic substances. Achieve Life Sciences is headquartered in Seattle, Washington. InvestingPro analysis reveals the company maintains a FAIR financial health score, with additional insights available in the comprehensive Pro Research Report, which provides deep-dive analysis of over 1,400 US stocks.
In other recent news, Achieve Life Sciences reported its fourth-quarter earnings, which did not meet analyst expectations. The company posted a loss of $0.36 per share, slightly worse than the anticipated $0.34 loss. Total (EPA:TTEF) operating expenses for the quarter were $12.2 million, contributing to a net loss of $12.4 million. Achieve Life Sciences ended the year with $34.4 million in cash, cash equivalents, and marketable securities. Despite the earnings shortfall, the company plans to submit a new drug application for cytisinicline to the U.S. Food and Drug Administration by the end of the second quarter of 2025. Achieve Life Sciences has completed enrollment in its ORCA-OL long-term exposure trial, meeting the required criteria for this submission. The company also reported positive outcomes from two data safety monitoring committee reviews, with no safety concerns identified. Additionally, Achieve Life Sciences recently appointed new board members and a Chief Financial Officer to bolster its strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.